M&A / Deals Cytospire hauls in $83M for a new type of T cell engager BioPharma DiveThe British biotechnology startup is making pan-gamma delta T cell engagers it says can address the limitations of similar, existing therapies.OncologyRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) BioPharma Dive The British biotechnology startup is making pan-gamma delta T cell engagers it says can address the limitations of similar, existing therapies. Oncology Read full story Post navigation Previous: Amneal Agrees to Acquire Kashiv BioSciences for Total Payment up to $1.1 BillionNext: Autoimmune disease biotech Odyssey sets terms for $225m IPO Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
